PCI Biotech Holding ASA (PCIB.OL)
NOK 1.33
(-0.38%)
NOK 1.33
(-0.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.22 Million NOK | 54.24% |
| 2022 | -54.1 Million NOK | 43.38% |
| 2021 | -82.69 Million NOK | -23.16% |
| 2020 | -69.63 Million NOK | 20.22% |
| 2019 | -85.11 Million NOK | -151.85% |
| 2018 | -44.51 Million NOK | 19.09% |
| 2017 | -43.42 Million NOK | -33.13% |
| 2016 | -33.02 Million NOK | -0.81% |
| 2015 | -32.62 Million NOK | 10.93% |
| 2014 | -36.46 Million NOK | -29.82% |
| 2013 | -29.32 Million NOK | -0.97% |
| 2012 | -25.24 Million NOK | -60.67% |
| 2011 | -13.68 Million NOK | -5.41% |
| 2010 | -16.14 Million NOK | 8.07% |
| 2009 | -17.55 Million NOK | -45.5% |
| 2008 | -12.06 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.05 Million NOK | 13.24% |
| 2024 Q2 | -4.05 Million NOK | 0.0% |
| 2023 Q2 | -6.23 Million NOK | -7.15% |
| 2023 FY | - NOK | 48.81% |
| 2023 Q4 | -4.67 Million NOK | 0.0% |
| 2023 Q3 | -4.67 Million NOK | 24.99% |
| 2023 Q1 | -5.81 Million NOK | 20.9% |
| 2022 Q4 | -7.35 Million NOK | 29.61% |
| 2022 FY | - NOK | 43.38% |
| 2022 Q1 | -16.48 Million NOK | 39.8% |
| 2022 Q2 | -14.27 Million NOK | 13.42% |
| 2022 Q3 | -10.44 Million NOK | 26.82% |
| 2021 Q4 | -27.38 Million NOK | -33.09% |
| 2021 Q2 | -17.45 Million NOK | 14.19% |
| 2021 Q1 | -20.33 Million NOK | 39.19% |
| 2021 FY | - NOK | -23.16% |
| 2021 Q3 | -20.57 Million NOK | -17.91% |
| 2020 Q2 | -20.94 Million NOK | -506.21% |
| 2020 Q3 | -20.4 Million NOK | 2.58% |
| 2020 Q4 | -33.44 Million NOK | -63.96% |
| 2020 FY | - NOK | 20.22% |
| 2020 Q1 | 5.15 Million NOK | 116.72% |
| 2019 FY | - NOK | -151.85% |
| 2019 Q2 | -25.79 Million NOK | -50.67% |
| 2019 Q4 | -30.83 Million NOK | -127.71% |
| 2019 Q3 | -13.54 Million NOK | 47.49% |
| 2019 Q1 | -17.11 Million NOK | -265.28% |
| 2018 FY | - NOK | 19.09% |
| 2018 Q4 | -4.68 Million NOK | 43.74% |
| 2018 Q3 | -8.32 Million NOK | -17.19% |
| 2018 Q2 | -7.1 Million NOK | 51.12% |
| 2018 Q1 | -14.53 Million NOK | 8.55% |
| 2017 Q4 | -15.89 Million NOK | -54.66% |
| 2017 FY | - NOK | -33.13% |
| 2017 Q1 | -9.63 Million NOK | -45.92% |
| 2017 Q2 | -6.99 Million NOK | 27.38% |
| 2017 Q3 | -10.28 Million NOK | -46.98% |
| 2016 Q1 | -7.13 Million NOK | 16.13% |
| 2016 FY | - NOK | -0.81% |
| 2016 Q4 | -6.6 Million NOK | 28.84% |
| 2016 Q3 | -9.27 Million NOK | -1.16% |
| 2016 Q2 | -9.16 Million NOK | -28.56% |
| 2015 Q3 | -9.19 Million NOK | -40.14% |
| 2015 FY | - NOK | 10.93% |
| 2015 Q1 | -7.65 Million NOK | 25.69% |
| 2015 Q2 | -6.56 Million NOK | 14.27% |
| 2015 Q4 | -8.5 Million NOK | 7.53% |
| 2014 Q1 | -9.12 Million NOK | -2.65% |
| 2014 Q2 | -8.13 Million NOK | 10.9% |
| 2014 Q3 | -8.25 Million NOK | -1.51% |
| 2014 Q4 | -10.3 Million NOK | -24.8% |
| 2014 FY | - NOK | -29.82% |
| 2013 Q1 | -6.82 Million NOK | 22.47% |
| 2013 Q2 | -5.41 Million NOK | 20.72% |
| 2013 Q3 | -6.56 Million NOK | -21.27% |
| 2013 Q4 | -8.88 Million NOK | -35.46% |
| 2013 FY | - NOK | -0.97% |
| 2012 Q1 | -6.2 Million NOK | -27.11% |
| 2012 Q4 | -8.8 Million NOK | -9.12% |
| 2012 Q3 | -8.06 Million NOK | -88.53% |
| 2012 Q2 | -4.27 Million NOK | 31.02% |
| 2012 FY | - NOK | -60.67% |
| 2011 Q1 | -4.02 Million NOK | 20.73% |
| 2011 FY | - NOK | -5.41% |
| 2011 Q2 | -5.11 Million NOK | -27.08% |
| 2011 Q3 | -3 Million NOK | 41.22% |
| 2011 Q4 | -4.88 Million NOK | -62.45% |
| 2010 Q3 | 1.04 Million NOK | 116.5% |
| 2010 Q1 | -5.68 Million NOK | -42.65% |
| 2010 FY | - NOK | 8.07% |
| 2010 Q2 | -6.35 Million NOK | -11.9% |
| 2010 Q4 | -5.07 Million NOK | -583.7% |
| 2009 Q4 | -3.98 Million NOK | 2.09% |
| 2009 Q3 | -4.06 Million NOK | 5.81% |
| 2009 Q2 | -4.32 Million NOK | 0.0% |
| 2009 FY | - NOK | -45.5% |
| 2008 FY | - NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arctic Bioscience AS | -37.78 Million NOK | 41.188% |
| Aqua Bio Technology ASA | -16.56 Million NOK | -34.131% |
| ArcticZymes Technologies ASA | 31.64 Million NOK | 170.225% |
| BerGenBio ASA | -191.8 Million NOK | 88.414% |
| Hofseth BioCare ASA | -70.6 Million NOK | 68.525% |
| Thor Medical ASA | -6.82 Million NOK | -225.406% |
| Ultimovacs ASA | -214.85 Million NOK | 89.657% |